Skip to main content
89bio, Inc. logo

89bio, Inc. — Investor Relations & Filings

Ticker · ETNB ISIN · US2825591033 US Manufacturing
Filings indexed 549 across all filing types
Latest filing 2026-02-13 Major Shareholding Noti…
Country US United States of America
Listing US ETNB

About 89bio, Inc.

https://www.89bio.com/

89bio, Inc. is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company focuses on creating innovative and potentially best-in-class treatments to address unmet medical needs in its target patient populations.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
Regulatory Filings 2025
Regulatory Filings
2025-11-20 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-13 English
15-12G
Regulatory Filings
2025-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.